High‐sensitivity C‐reactive protein and risk of type 2 diabetes: A nationwide cohort study and updated meta‐analysis

Yang, Xue; Tao, Siyu; Peng, Jie; Zhao, Jian; Li, Sheyu; Wu, Nianwei; Wen, Ying; Xue, Qingping; Yang, Chunxia

doi:10.1002/dmrr.3446

Cited by 22 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exploratory subgroup analyses were conducted by stratifying the meta-analysis by region (Europe, Asia, or America), diabetic status (population with or without diabetes), the adoption of multivariate model (adopt or not), age (<60 years, ≥60 years, or not available), risk of bias (poor, fair, and good), and timing for metformin administration (before and after the diagnosis of COVID-19). We applied visual funnel plots, Egger's tests, and Begg's tests to assess for potential publication bias ( 23 ). In addition, we conducted a sensitivity analysis by excluding the study with the largest number of sample size and an influencing analysis by successively excluding one study at a time to evaluate whether the result was robust.…”

Section: Methodsmentioning

confidence: 99%

Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis

Yang

Yan

et al. 2021

Front. Med.

Self Cite

View full text Add to dashboard Cite

Importance/Background: The coronavirus disease (COVID-19) pandemic is a critical public health issue. Evidence has shown that metformin favorably influences COVID-19 outcomes. This study aimed to assess the benefits and risks of metformin in COVID-19 patients.Methods: We searched the PubMed, Embase, Cochrane Library, and Chinese Biomedical Literature Database from inception to February 18, 2021. Observational studies assessing the association between metformin use and the outcomes of COVID-19 patients were included. The primary outcome was mortality, and the secondary outcomes included intubation, deterioration, and hospitalization. Random-effects weighted models were used to pool the specific effect sizes. Subgroup analyses were conducted by stratifying the meta-analysis by region, diabetic status, the adoption of multivariate model, age, risk of bias, and timing for adding metformin.Results: We identified 28 studies with 2,910,462 participants. Meta-analysis of 19 studies showed that metformin is associated with 34% lower COVID-19 mortality [odds ratio (OR), 0.66; 95% confidence interval (CI), 0.56–0.78; I2 = 67.9%] and 27% lower hospitalization rate (pooled OR, 0.73; 95% CI, 0.53–1.00; I2 = 16.8%). However, we did not identify any subgroup effects. The meta-analysis did not identify statistically significant association between metformin and intubation and deterioration of COVID-19 (OR, 0.94; 95% CI, 0.77–1.16; I2 = 0.0% for intubation and OR, 2.04; 95% CI, 0.65–6.34; I2 = 79.4% for deterioration of COVID-19), respectively.Conclusions: Metformin use among COVID-19 patients was associated with a reduced risk of mortality and hospitalization. Our findings suggest a relative benefit for metformin use in nursing home and hospitalized COVID-19 patients. However, randomized controlled trials are warranted to confirm the association between metformin use and COVID-19 outcomes.Study Registration: The study was registered on the PROSPERO on Feb 23, 2021 (CRD42021238722).

show abstract

Section: Methodsmentioning

confidence: 99%

Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis

Yang

Yan

et al. 2021

Front. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The other markers of inflammation are serum ferritin, serum albumin, and serum fibrinogen. Among these inflammatory markers, CRP has been found to be strong and independent for both the development of incident diabetes and cardiovascular complications [54].…”

Section: The Metabolic Syndrome and Diabetes Mellitusmentioning

confidence: 99%

Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review

Banait¹,

Wanjari²,

Danade³

et al. 2022

Cureus

View full text Add to dashboard Cite

Non-communicable diseases like cardiovascular diseases, cerebrovascular diseases, diabetes mellitus, and cancer are very common causes of death worldwide. Therefore, the need to search for novel, affordable, and easily accessible biomarkers and risk factors for non-communicable diseases continues, which can predict the future risk of having these diseases with greater accuracy and precision. In this context, among available biomarkers, high-sensitivity C-reactive protein (Hs-CRP) is considered to be the best-suited marker. Various drug intervention trials demonstrated positive results in reducing Hs-CRP in individuals with raised levels. Numerous pharmacological and non-pharmacologic interventions in the form of lifestyle modifications, exercise, and cessation of smoking are being investigated to study their effect on reducing serum C-reactive protein (CRP) levels.This review article discusses the role of Hs-CRP and its isoforms in the pathogenesis of various disease conditions, factors affecting its serum concentration, its prognostic value, and its comparison with other risk factors. Further, its clinical significance in chronic inflammatory and degenerative diseases of the nervous system and other common non-communicable diseases, including recent advances in the management of various diseases, has also been discussed.

show abstract

“…In this study, CRP, a well-established marker of systemic inflammation in metabolic syndrome (33), tend to be identified as an independent risk factor of cancer in young adults. Elevated CRP has been associated with an increased risk of diabetes in middle-aged and elderly Chinese (34). Chronic inflammation related to glucose intolerance might play an essential role in carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

Glucose Intolerance and Cancer Risk: A Community-Based Prospective Cohort Study in Shanghai, China

Lin

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundCancer becomes the leading cause of premature death in China. Primary objective of this study was to determine the major risk factors especially glucose intolerance for cancer prophylaxis.MethodsA cluster sampling method was applied to enroll 10,657 community-based adults aged 15-92 years in Shanghai, China in 2013. A structured questionnaire and physical examination were applied in baseline survey. Prediabetes was diagnosed using 75-g oral glucose tolerance test. After excluding 1433 subjects including 224 diagnosed with cancer before and 1 year after baseline survey, the remaining 9,224 subjects were followed-up to December 31, 2020.ResultsA total of 502 new cancer cases were diagnosed. The cancer incidence was 10.29, 9.20, and 5.95/1,000 person-years in diabetes patients, those with prediabetes, and healthy participants, respectively (p<0.001). The multivariate Cox regression analysis indicated that age, prediabetes and diabetes, were associated with an increased risk of cancer in those <65 years, the hazard ratios (95% confidence interval) for prediabetes and diabetes were, 1.49(1.09-2.02) and 1.51(1.12-2.02), respectively. Glucose intolerance (prediabetes and diabetes) were associated with increased risks of stomach cancer, colorectal cancer, and kidney cancer in those <65 years. Anti-diabetic medications reduced the risk of cancer caused by diabetes. The multivariate Cox analysis showed that age, male, <9 years of education, and current smoking were associated with increased risks of cancer in those ≥65 years independently.ConclusionsGlucose intolerance is the prominent cancer risk factor in adults <65 years. Lifestyle intervention and medications to treat glucose intolerance help prevent cancer in this population.

show abstract

High‐sensitivity C‐reactive protein and risk of type 2 diabetes: A nationwide cohort study and updated meta‐analysis

Cited by 22 publications

References 30 publications

Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis

Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis

Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review

Glucose Intolerance and Cancer Risk: A Community-Based Prospective Cohort Study in Shanghai, China

Contact Info

Product

Resources

About